Trial · NCT01722331
Adverse events357
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 357
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Tildrakizumab 200 mg (Part 1) | 20 | 308 | 20 |
| other | Nasopharyngitis | Infections and infestations | Tildrakizumab 100 mg (Part 1) | 24 | 309 | 26 |
| other | Nasopharyngitis | Infections and infestations | Placebo (Part 1) | 8 | 154 | 8 |
| other | Nasopharyngitis | Infections and infestations | Tildrakizumab 200 mg (Part 2) | 17 | 370 | 18 |
| other | Nasopharyngitis | Infections and infestations | Tildrakizumab 100 mg (Part 2) | 24 | 374 | 24 |
| other | Nasopharyngitis | Infections and infestations | Tildrakizumab 200 mg (Part 3) | 44 | 360 | 55 |
| other | Nasopharyngitis | Infections and infestations | Tildrakizumab 100 mg (Part 3) | 48 | 316 | 66 |
| other | Psoriasis | Skin and subcutaneous tissue disorders | Tildrakizumab 200 mg (Part 1) | 0 | 308 | 0 |
| other | Psoriasis | Skin and subcutaneous tissue disorders | Tildrakizumab 100 mg (Part 1) | 2 | 309 | 2 |
| other | Psoriasis | Skin and subcutaneous tissue disorders | Placebo (Part 1) | 8 | 154 | 8 |
| other | Psoriasis | Skin and subcutaneous tissue disorders | Tildrakizumab 200 mg (Part 2) | 3 | 370 | 4 |
| other | Psoriasis | Skin and subcutaneous tissue disorders | Tildrakizumab 100 mg (Part 2) | 2 | 374 | 2 |
| other | Psoriasis | Skin and subcutaneous tissue disorders | Tildrakizumab 200 mg (Part 3) | 9 | 360 | 9 |
| other | Psoriasis | Skin and subcutaneous tissue disorders | Tildrakizumab 100 mg (Part 3) | 9 | 316 | 9 |
| other | Upper respiratory tract infection | Infections and infestations | Tildrakizumab 200 mg (Part 1) | 15 | 308 | 15 |
| other | Upper respiratory tract infection | Infections and infestations | Tildrakizumab 100 mg (Part 1) | 10 | 309 | 10 |
| other | Upper respiratory tract infection | Infections and infestations | Placebo (Part 1) | 9 | 154 | 10 |
| other | Upper respiratory tract infection | Infections and infestations | Tildrakizumab 200 mg (Part 2) | 20 | 370 | 21 |
| other | Upper respiratory tract infection | Infections and infestations | Tildrakizumab 100 mg (Part 2) | 16 | 374 | 17 |
| other | Upper respiratory tract infection | Infections and infestations | Tildrakizumab 200 mg (Part 3) | 37 | 360 | 43 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01722331/events